You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Morquio A therapy integrating gene transfer with lectin-enhanced enzyme delivery to treat multisystemic clinical impairments of rare metabolic childhood diseases
SBC: BIOSTRATAGIES LC Topic: NICHDMucopolysaccharidosis Type IVA (MPS-IVA; also called Morquio A Syndrome) is a rare genetic childhood disorder characterized by multi-systemic pathologies affecting the respiratory, cardiovascular, musculoskeletal, and central nervous systems leading to devastating quality-of-life and early death. The disease is due to deficiencies in N-acetylgalactosamine-6-sulfate sulfatase (GALNS) causing progre ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Custom Sensor Manufacturing and Regulatory Preparation Assistance for Novel Intraoperative Ureter Detection Device
SBC: BRITESEED, LLC Topic: NICHDPROJECT SUMMARY/ABSTRACT The goal of this small business innovation research grant is to commercialize a cost-effective and contrast-free intraoperative ureter detection system, which integrates into a laparoscopic vessel sealing device to identify ureters in real-time and prevent iatrogenic injuries. 70% of iatrogenic ureteral injuries are detected postoperatively, up to 30 days after hospital di ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
A proprietary digital platform for precision patient identification and enrollment of clinical trials for rare kidney diseases
SBC: Nephropathology Associates, PLC Topic: 400Project Summary The goal of this Direct to Phase II program is to develop and test the efficacy of a Precision Medicine Clinical Trials Enrollment Platform for kidney diseases. Approximately half of randomized controlled trials do not meet their recruiting target. Enrolling trials targeting rare kidney diseases is particularly challenging with many conditions subject to stratification and sub-typi ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Production of Natural Deoxysugars for Use in Chemical Synthesis of Glycosides
SBC: MIDWEST BIOPROCESSING CENTER LLC Topic: 300Project SummaryThe goal of the proposal presented herein is to produce naturally occurring 6-deoxysugars, including di- and tri-deoxysugars, amino sugars and branched-chain sugars. These specialized hexoses are found as important structural components throughout plant and microbial secondary metabolites, often playing a crucial role in conferring activity in bioactive natural products, such as ant ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Implantable Microarray Probe for Real-Time Glutamate and GABA Detection
SBC: ALCORIX CO Topic: 105Project Summary This STTR proposal will focus on developing and testing a novel, first-on-the-market implantable biosensor for in vivo, real-time sensing of gamma-aminobutyric acid (GABA) and glutamate (GLU) for animal studies. GABA and GLU are neurotransmitters (NTs) that are essential for information processing and plasticity, memory, and other functions. GLU is the major excitatory NT and GABA ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
REPLACING PLASTIC WITH BIODEGRADABLE PACKGING IN FOOD SERVICE
SBC: Biomass Energy Systems, Inc. Topic: DLA211003This proposal follows the DLA SBIR Phase 1 Contract SP4701-21-P-0075. It seeks resources to move to Phase 2 so that the lessons learned and data developed in Phase 1 will further expand on the solution, including the field demonstration for replacing the plastic packaging in food service with the biodegradable Cellulosic Bio-Polymer (CBP) packaging to address military needs. Phase 1 was a great le ...
SBIR Phase II 2023 Department of DefenseDefense Logistics Agency -
Gene Therapy that Systemically Produces Brain-penetrating Replacement Enzyme for MPS IIIA (Sanfilippo A Syndrome)
SBC: BIOSTRATAGIES LC Topic: 105PROJECT SUMMARY In this Direct-to-Phase II SBIR, BioStrategies LC proposes to advance the development of a novel AAV- based gene therapy for mucopolysaccharidosis type IIIA (MPS IIIA, also known as Sanfilippo A syndrome). In contrast to other gene therapies in development for MPS IIIA, BioStrategies’ approach is designed to achieve a systemic therapeutic effect, including delivery of a functiona ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Methods for Fast and Efficient Oxygen Imaging
SBC: O2M TECHNOLOGIES LLC Topic: 102Abstract Intermittent or acute/cyclic hypoxia in tumors, with frequencies between a few cycles per minute to hours, is receiving increased attention because this type of hypoxia has been reported to have an influence on tumor malignancy as well as treatment resistance via increased expression of pro-survival pathways. Fast oxygen imaging methods are needed for the measurement of acute tumor hypoxi ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Optimizing NGF for Topical Treatment of Glaucoma
SBC: HUMAN CELL CO Topic: NEIABSTRACTGlaucoma is a leading cause of irreversible vision loss, which is characterized by progressive degeneration of retinal ganglion cells (RGC) and their optic nerve axons. While age is a key risk factor, elevated intraocular pressure (IOP) is the only modifiable risk factor, with topical IOP-lowering drugs as the first line treatment. However, RGC degeneration and vision loss continues in hal ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Selective Activators of Nrf2 for Neurodegenerative Disease
SBC: GROVE BIOPHARMA, INC. Topic: 105Protein-like polymers (PLPs) are next generation biotherapeutics with the potential to improve treatment outcomes for patients suffering from devastating neurodegenerative diseases. We have developed a lead PLP that disrupts the Keap1-Nrf2 intracellular protein-protein interaction (PPI) that restricts the therapeutic activity of Nrf2 (nuclear factor-erythroid factor 2-related factor 2), a validate ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health